Natraj Ammakkanavar, MD
Medical Oncology · Indianapolis, INNPI 1376850461
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,028 of the $129,364 with a category attached, or 80.4%. E.r. Squibb & Sons, L.L.C. accounts for 74.2% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $44,150, more than ten times the $2,381 reported in 2019. Among medical oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $493.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$96K
- AstraZeneca$23K
- Gilead$4K
- Regeneron Healthcare Solutions, Inc.$2K
- Eli Lilly$1K
- Sanofi$392
- plus $3K from 32 others
Across 531 payments — averaging $7554.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.7M
- AbbVie$1.1M
- Pfizer$433K
- Merck$383K
- Seagen Inc.$328K
- Servier Bioinnovation$75K
- plus $30K from 2 others
What the payments were for
- Consulting fees$16,95513%
- Speaking & faculty fees$104,02880%
- Travel & lodging$1,5541%
- Food & beverage$6,6835%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 69 | $95,966 |
| AstraZeneca(2 entities) | 27 | $22,835 |
| Gilead(2 entities) | 6 | $4,042 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,861 |
| Eli Lilly | 3 | $1,168 |
| Sanofi | 11 | $392 |
| Amgen | 13 | $351 |
| Genentech USA, Inc. | 19 | $307 |
| Novartis | 18 | $290 |
| Merck | 20 | $281 |
| Adaptive Biotechnologies Corporation | 2 | $228 |
| Johnson & Johnson(2 entities) | 12 | $209 |
| Pfizer | 16 | $199 |
| Daiichi Sankyo Inc. | 3 | $161 |
| Incyte Corporation | 4 | $149 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $125 |
| Genmab U.S., Inc. | 1 | $101 |
| Beigene USA, Inc. | 1 | $97 |
| ADC Therapeutics America, Inc. | 1 | $92 |
| Eisai Inc. | 5 | $69 |
| Tempus AI, Inc | 1 | $61 |
| Bristol Myers Squibb | 2 | $44 |
| Puma Biotechnology, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Sandoz | 2 | $23 |
| Aurobindo Pharma USA, Inc. | 1 | $21 |
| Verastem, Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Seagen Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$129,364 in reported general payments places this provider in the 95th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 51 | $802,706 |
| XtandiEnzalutamide | 42 | $576,321 |
| CalquenceAcalabrutinib Maleate | 35 | $451,022 |
| ImbruvicaIbrutinib | 33 | $422,018 |
| NubeqaDarolutamide | 35 | $371,511 |
| IbrancePalbociclib | 23 | $309,976 |
| EliquisApixaban | 270 | $309,222 |
| BrukinsaZanubrutinib | 28 | $302,887 |
| CabometyxCabozantinib S-Malate | 13 | $292,465 |
| BraftoviEncorafenib | 19 | $285,932 |
| BosulifBosutinib | 21 | $265,072 |
| Lenalidomide | 16 | $196,199 |
| MektoviBinimetinib | 16 | $172,162 |
| VerzenioAbemaciclib | 11 | $149,425 |
| ErleadaApalutamide | 12 | $141,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis, Bosulif | $199 | $884,270314 claims |
| Bristol Myers SquibbRevlimid | $44 | $802,70651 claims |
| Astellas Pharma US IncXtandi | $11 | $576,32142 claims |
| AstraZenecaCalquence | $22,835 | $451,02235 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $125 | $422,01833 claims |
| BayerNubeqa | $13 | $371,51135 claims |
| Beigene USA, Inc.Brukinsa | $97 | $302,88728 claims |
| Johnson & JohnsonErleada, Xarelto | $209 | $180,67245 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $29 | $150,17537 claims |
| NovartisPromacta | $290 | $83,00211 claims |
| SandozEnoxaparin Sodium | $23 | $12,80119 claims |
| Daiichi Sankyo Inc.Savaysa | $161 | $9,57312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Indianapolis
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Daniel SonnenburgIndianapolis$37K
- Sumeet BhatiaIndianapolis$24K
- Michael SlaughterIndianapolis$17K
- Elsayed AlyIndianapolis$9K
- Anuj AgarwalaIndianapolis$8K
- Sead BeganovicIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.